These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 25004822)

  • 1. Prodrug applications for targeted cancer therapy.
    Giang I; Boland EL; Poon GM
    AAPS J; 2014 Sep; 16(5):899-913. PubMed ID: 25004822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
    Yoon KJ; Potter PM; Danks MK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodrug strategy for cancer cell-specific targeting: A recent overview.
    Zhang X; Li X; You Q; Zhang X
    Eur J Med Chem; 2017 Oct; 139():542-563. PubMed ID: 28837920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrugs in medicinal chemistry and enzyme prodrug therapies.
    Walther R; Rautio J; Zelikin AN
    Adv Drug Deliv Rev; 2017 Sep; 118():65-77. PubMed ID: 28676386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteases as activators for cytotoxic prodrugs in antitumor therapy.
    Weidle UH; Tiefenthaler G; Georges G
    Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies on the development of small molecule anticancer drugs for targeted therapy.
    Lu YH; Gao XQ; Wu M; Zhang-Negrerie D; Gao Q
    Mini Rev Med Chem; 2011 Jun; 11(7):611-24. PubMed ID: 21699492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum(IV) Prodrugs.
    Venkatesh V; Sadler PJ
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments with targeted enzymes in cancer therapy.
    Bagshawe KD; Sharma SK; Burke PJ; Melton RG; Knox RJ
    Curr Opin Immunol; 1999 Oct; 11(5):579-83. PubMed ID: 10508703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latent Warheads for Targeted Cancer Therapy: Design and Synthesis of pro-Pyrrolobenzodiazepines and Conjugates.
    Vlahov IR; Qi L; Kleindl PJ; Santhapuram HK; Felten A; Parham GL; Wang K; You F; Vaughn JF; Hahn SJ; Klein HF; Vetzel M; Reddy JA; Nelson M; Nicoson J; Leamon CP
    Bioconjug Chem; 2017 Dec; 28(12):2921-2931. PubMed ID: 29211454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted enzyme prodrug therapies.
    Schellmann N; Deckert PM; Bachran D; Fuchs H; Bachran C
    Mini Rev Med Chem; 2010 Sep; 10(10):887-904. PubMed ID: 20560876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
    Devkota L; Lin CM; Strecker TE; Wang Y; Tidmore JK; Chen Z; Guddneppanavar R; Jelinek CJ; Lopez R; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
    Bioorg Med Chem; 2016 Mar; 24(5):938-956. PubMed ID: 26852340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Trends in
    Sun IC; Yoon HY; Lim DK; Kim K
    Bioconjug Chem; 2020 Apr; 31(4):1012-1024. PubMed ID: 32163277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodrugs for targeted cancer therapy.
    Souza C; Pellosi DS; Tedesco AC
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):483-502. PubMed ID: 31055990
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.
    HariKrishna D; Rao AR; Krishna DR
    Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macromolecular Prodrugs Containing Organoiron-Based Compounds in Cancer Research: A Review.
    Mukaya EH; Mbianda XY
    Mini Rev Med Chem; 2020; 20(9):726-738. PubMed ID: 31702511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prodrugs in photodynamic anticancer therapy.
    Musiol R; Serda M; Polanski J
    Curr Pharm Des; 2011; 17(32):3548-59. PubMed ID: 22074426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.